DEPLOYDatabase

Robot model

IpsiHand

biometriccommercialby NeuroLutions

FDA-cleared non-invasive BCI for stroke rehabilitation.

Track IpsiHand
Manufacturer
NeuroLutions
Form factor
biometric
Maturity
commercial
Lifecycle
active
Deployments
2

Overview

FDA-cleared non-invasive BCI for stroke rehabilitation. First FDA-cleared BCI for stroke recovery. It is a biometric system designed for physical AI applications. Key specifications include Form Factor: biometric, Maturity: commercial.

Verified vs. claimed

Maturity stage
commercial(Commercially deployed with revenue-generating operations.)
Sources on file
View all sources →

Key facts

FDA authorization (reported, Apr 2021)

Received FDA Breakthrough Device designation and De Novo authorization; WashU called it the first stroke-rehab device relying on a brain-computer interface.

Device (reported)

A wearable hand-and-wrist exoskeleton driven by ipsilateral brain signals, for home or clinic use.

Origins (reported)

Co-founded in 2007 by Eric Leuthardt and Daniel Moran on technology licensed from Washington University.

Trial regimen (reported)

Trial users trained about five days a week for 12 weeks.

Data & sources

Web sources

1

1 source backing this record.View all →

Pricing

No verified price is on record for IpsiHand. Physical-AI systems are often sold through enterprise contracts or operated as a service rather than at a public list price.

How DEPLOY tracks pricing

Deployments (2)

IpsiHand on the deployment map

View the global map

Where IpsiHand is verified operating. Explore the deployment map by place and type.

Free to use on your site, with a link back to DEPLOY.

Recent activity

Every change to this record is dated, sourced, and independently verified where marked.

Full change history →

Safety record

No incidents on record for IpsiHand.

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Sources (1)

  1. https://medicine.washu.edu/news/stroke-recovery-device-using-brain-computer-interface-receives-fda-market-authorization/

Mentioned on (1)

Registry pages whose text names IpsiHand.

Companies (1)

NeuroLutions

Common questions

What is IpsiHand?
FDA-cleared non-invasive BCI for stroke rehabilitation. First FDA-cleared BCI for stroke recovery. It is a biometric system designed for physical AI applications. Key specifications include Form Factor: biometric, Maturity: commercial.
How much does IpsiHand cost?
IpsiHand's price is not publicly disclosed. DEPLOY has no verified price on record for IpsiHand from NeuroLutions. Physical-AI systems like this are often sold through enterprise contracts or operated as a service rather than at a public list price; check the manufacturer for the latest.
Is IpsiHand actually deployed in the real world?
Yes. IpsiHand is independently verified in real-world operation on the DEPLOY registry, confirmed at named deployment sites with primary sources: not a concept, render, or demo-only.
Who makes IpsiHand?
IpsiHand is made by NeuroLutions, based in St. Louis, Missouri, USA, founded in 2007.
Where is IpsiHand deployed?
2 verified deployments of IpsiHand are on the DEPLOY registry, including at United States, Germany, Europe.
Can you buy IpsiHand?
IpsiHand is in commercial deployment and is sold to operators; contact the manufacturer to buy, and see the pricing section for any recorded price.
What are alternatives to IpsiHand?
On the DEPLOY registry, comparable biometric robots to IpsiHand include Blackrock Neuroport Array, Synchron Stentrode, BrainQ Non-Invasive BCI, Neko Body Scan.
How does IpsiHand compare to Blackrock Neuroport Array?
IpsiHand and Blackrock Neuroport Array (Blackrock Neurotech · 5 deployments) are both biometric robots on the DEPLOY registry. IpsiHand has 2 verified deployments on record. Compare both records for specs, safety, deployments, and verified-vs-claimed autonomy.
Is IpsiHand a top biometric?
On DEPLOY's intelligence score, which blends verified deployments, safety, adoption, media, and IP signals, IpsiHand ranks in roughly the top 55% of biometric models tracked by the registry.
What is IpsiHand's maturity stage?
IpsiHand is at the commercial stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Commercial stage means production-grade deployments are operating at named customer sites.
Is IpsiHand safe?
IpsiHand has no incidents on record in the DEPLOY registry. This does not constitute a safety guarantee; it reflects the incidents DEPLOY has tracked and verified to date.
Methodology: Verified · 1 source (no primary) · last reviewed 2026-10-10

Verification posture

Verified

Low confidence

Review state

Stable

Last reviewed 2026-10-10

Maturity + lifecycle

Maturity stage: commercial

Lifecycle: active

Architectural position

Cohort: biometric

Sources by quality tier

1
unclassified
Unclassified source

The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.

Methodology surface for IpsiHand.

Recent coverage

IpsiHand in third-party press

Kandu trial highlights positive outcomes with IpsiHand BCI system

Feb 12, 2026

Stroke-recovery device using brain-computer interface receives FDA market authorization

Oct 5, 2024

IpsiHand stroke-recovery device named product of year by science society

Oct 5, 2024